Curated News
By: NewsRamp Editorial Staff
July 16, 2026
NeuroOne and Mayo Clinic Join Forces Against Childhood Brain Cancer
TLDR
- NeuroOne's drug delivery platform, partnered with Mayo Clinic, offers a competitive edge in targeting pediatric brain tumors with novel therapy.
- The study uses NeuroOne's device for precision intracranial drug delivery and real-time neural recording to evaluate enhanced drug retention via efflux modulation.
- This collaboration aims to improve treatment for children with aggressive brain cancer, potentially saving lives and reducing suffering.
- NeuroOne's technology combines drug delivery with neural recording, enabling real-time monitoring during brain tumor treatment.
Impact - Why it Matters
This news matters because pediatric diffuse midline glioma is one of the most aggressive and difficult-to-treat childhood brain cancers, with limited treatment options. The collaboration between NeuroOne and Mayo Clinic, supported by the Children's Cancer Research Fund, aims to develop a novel therapy that could improve drug delivery to brain tumors, potentially increasing survival rates and quality of life for affected children. By combining precision drug delivery with real-time neural monitoring, this approach could set a new standard for treating brain cancers and other neurological disorders, offering hope to patients and families facing these devastating diagnoses.
Summary
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has announced a collaboration with Mayo Clinic to evaluate a novel treatment approach for pediatric diffuse midline glioma (DMG), an aggressive childhood brain cancer. The research is funded by a grant from the Children's Cancer Research Fund (CCRF) awarded to Mayo Clinic investigators Dr. David Daniels and Dr. Liang Zhang. The project aims to overcome the challenge of maintaining therapeutic drug concentrations within brain tumors by using convection-enhanced delivery (CED) combined with modulation of drug efflux mechanisms to prolong drug retention. The study will utilize NeuroOne's investigational drug delivery neural device, which integrates precision intracranial drug delivery with simultaneous neural recording, providing real-time physiologic monitoring during treatment.
This collaboration marks a significant expansion of NeuroOne's drug delivery platform, which already includes FDA-cleared products like Evo® Cortical Electrodes and OneRF® Ablation System. The company's technology is designed to enable targeted intracranial therapies while offering diagnostic and therapeutic functions. The research will begin with large animal studies, with potential to move to human studies if successful. NeuroOne's Chief Business Officer, David Wambeke, expressed enthusiasm about supporting Mayo Clinic's efforts to develop new treatments for children with devastating brain tumors.
The growing interest from leading academic investigators and biopharmaceutical companies in NeuroOne's drug delivery platform underscores its potential as an enabling technology for CNS disorders. This initiative reflects a broader trend toward precision medicine in neurology, combining targeted drug delivery with real-time monitoring to improve outcomes. The CCRF award represents an important milestone in advancing this innovative therapeutic approach toward clinical evaluation.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, NeuroOne and Mayo Clinic Join Forces Against Childhood Brain Cancer
